← ADMA BIOLOGICS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($19.5m) ($43.8m) ($65.7m) ($48.3m) ($75.7m) ($71.6m) ($65.9m) ($28.2m) $197.7m $146.9m
Depreciation, Depletion and Amortization $470k $1.5m $2.6m $2.4m $3.2m $4.8m $6.4m $7.6m $7.7m $8.0m
Amortization of Debt Issuance Costs $0 — — — — — — $0 $0 ($2.2m)
Amortization of Intangible Assets — $1.2m $845k $845k $715k $715k $715k $724k $388k $144k
Deferred Income Tax Expense (Benefit) — — — — — — $0 $0 ($84.3m) $11.0m
Share-based Payment Arrangement, Noncash Expense $1.3m $1.6m $2.2m $2.7m $2.9m $3.5m $5.2m $6.2m $13.6m $20.0m
Goodwill, Impairment Loss — — — — — $0 $0 $0 $0 $0
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property — ($10k) ($122k) ($207k) $82k ($221k) ($427k) ($182k) ($106k) ($9k)
Gain (Loss) on Extinguishment of Debt $0 ($1.2m) $0 ($10.0m) $992k $0 ($6.7m) ($26.2m) ($1.2m) ($3.3m)
Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $0 $0 $0 ($72.0m) $35.7m
Interest Expense Nonoperating — — — — — — — — $13.9m $7.1m
Operating Lease, Expense — — — — — $1.4m $2.1m $2.4m $2.4m $2.4m
Other Nonoperating Income (Expense) — ($10k) ($127k) ($227k) ($129k) ($252k) ($634k) ($287k) ($193k) ($212k)
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $94k $2.9m ($2.5m) $2.1m ($9.8m) $15.3m ($13.1m) $11.9m $22.6m $108.4m
Increase (Decrease) in Inventories $1.6m ($589k) $6.0m $34.7m ($28.5m) $43.2m $38.6m $9.6m ($2.7m) $36.2m
Increase (Decrease) in Accounts Payable $477k $2.8m ($20k) $3.3m $1.9m $1.4m $800k $3.8m $4.2m $2.3m
Proceeds from Stock Options Exercised $0 $8k $13k $75k $13k $0 $175k $1.1m $7.5m $3.0m
General and Administrative Expense $8.5m $18.1m $22.5m $25.9m $35.1m — — — — —
Goodwill — $3.5m $3.5m $3.5m $3.5m $3.5m $3.5m $3.5m $3.5m $3.5m
Investment Income, Interest — — — — $288k $35k $45k $1.6m $2.1m $1.9m
Nonoperating Income (Expense) ($2.2m) ($4.4m) ($5.5m) ($6.9m) ($10.8m) ($13.3m) ($26.5m) ($49.9m) ($13.3m) ($8.8m)
Operating Expenses $28.0m $62.1m $77.3m $70.8m $107.1m $59.5m $74.6m $67.3m $80.6m $101.3m
Payments of Financing Costs — — — — — — $2.8m $2.4m $0 $0
Gain (Loss) on Derivative Instruments, Net, Pretax $0 — — — — — — — — —
Net Cash Provided by (Used in) Operating Activities ($18.3m) ($37.3m) ($62.7m) ($76.2m) ($102.0m) ($112.4m) ($59.5m) $8.8m $118.7m $50.4m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $73k $2.7m $2.1m $3.8m $12.7m $13.5m $13.9m $4.8m $8.2m $22.6m
Net Cash Provided by (Used in) Investing Activities $905k $15.2m ($2.1m) ($3.8m) ($12.7m) ($13.5m) ($13.9m) ($5.0m) ($8.6m) ($21.9m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt — $30.0m $0 $72.5m $27.5m — — — — —
Repayments of Long-term Debt — — — — $13.9m — — — — —
Proceeds from Issuance of Common Stock $14.1m $39.2m $42.9m $48.4m $131.2m $121.1m $64.6m $0 $0 —
Payments for Repurchase of Common Stock — — — — — — — — — $31.9m
Net Cash Provided by (Used in) Financing Activities $16.8m $60.8m $42.9m $80.0m $143.9m $121.0m $108.9m ($39.0m) ($58.3m) ($44.0m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect ($526k) $38.7m ($21.9m) ($3k) $29.2m ($4.8m) $35.4m ($35.2m) $51.8m ($15.5m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $48.6m $26.8m $26.8m — $51.1m $86.5m $51.4m $103.1m $87.6m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities — $2.3m $4.4m $8.1m $8.1m $11.2m $13.9m $18.1m $10.7m $9.1m
Income Taxes Paid, Net — — — — $0 ($62k) ($2.9m) ($1.4m) ($5.0m) $19.7m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.